Irving’s Caris Life Sciences Raises $830M to Grow Its Precision Medicine Platform for Cancer Care

by | May 12, 2021
Now valued at more than $7.8 billion, Caris specializes in AI-powered genetic sequencing for personalized cancer treatments. The massive capital raise follows a $310 million round in October and boosts the 13-year-old company's total funding to about $1.3 billion.
Caris Life Sciences Raises $310M to Continue Rapidly Growing in the Precision Medicine Market
by | Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
Irving-based Caris Life Sciences is Expanding its Footprint Here With a New Corporate Park
by | Aug 20, 2019
The Caris Life Sciences Corporate Park in Irving will increase R&D capabilities with a state-of-the-art precision medicine laboratory, create more than 500 jobs in the region, and help Caris continue to "reinvent cancer care."
Caris Life Sciences Acquires Pharmatech to Pair Patients with Clinical Trials, Faster
by | May 2, 2019
Using a patient's molecular makeup, Caris and Pharmatech aim to find the perfect clinical trial for each cancer patient—and enroll them in as little as 10 days.